[1]张玲,牛萍萍,朱玉梅,等.龙香平喘胶囊治疗支气管哮喘临床疗效观察[J].西部中医药,2023,36(10):129-132.[doi:10.12174/j.issn.2096-9600.2023.10.27]
　ZHANG Ling,NIU Pingping,ZHU Yumei,et al.Observation on Clinical Effects of Longxiang Asthma-relieving Capsules in Treating Bronchial Asthma[J].Western Journal of Traditional Chinese Medicine,2023,36(10):129-132.[doi:10.12174/j.issn.2096-9600.2023.10.27]
点击复制

龙香平喘胶囊治疗支气管哮喘临床疗效观察
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年10期
页码:
129-132
栏目:
出版日期:
2023-10-15

文章信息/Info

Title:
Observation on Clinical Effects of Longxiang Asthma-relieving Capsules in Treating Bronchial Asthma
作者:
张玲1, 牛萍萍2, 朱玉梅3, 杨璐3, 陈信义3
1.云南中医药大学，云南 昆明 650500
2.山东华信制药集团股份有限公司，山东 菏泽 274000
3.北京中医药大学东直门医院，北京 100700
Author(s):
ZHANG Ling1, NIU Pingping2, ZHU Yumei3, YANG Lu3, CHEN Xinyi3
1.Yunnan University of TCM, Kunming 650500, China
2.Shandong Huaxin Pharmaceutical Group Corporation, Heze 274000, China
3.Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 100700, China
关键词:
支气管哮喘; 龙香平喘胶囊; 急性发作期
Keywords:
bronchial asthma; asthma-relieving capsules; acute exacerbation
分类号:
R562.2+5
DOI:
10.12174/j.issn.2096-9600.2023.10.27
文献标志码:
B
摘要:
目的观察龙香平喘胶囊治疗支气管哮喘的临床有效性与安全性。 方法按照国家食品药品监督管理总局GCP规范，采用随机双盲、双模拟、阳性药平行对照、多中心研究原则。治疗组109例服用龙香平喘胶囊加模拟剂，对照组108例服用蠲哮片加模拟剂。两组病例进行14天的双盲期治疗，治疗结束后统计疗效。 结果两组治疗后第1秒用力呼气容积/用力肺活量（forced expiratory volume in one second/forced vital capacity，FEVl／FVC）及呼气峰值流量（peak expiratory flow PEF）均比治疗前增高（P＜0.01），且两组疗效相当（P＞0.05）。治疗后，两组肺功能疗效比较，差异无统计学意义（P＞0.05）。两组治疗后第14、21天时证候总积分均较第7天降低（P＜0.01），且治疗组治疗第14、21天时证候总积分低于对照组同期（P＜0.01）。两组治疗后证候疗效优于治疗前（P＜0.01），且治疗组治疗第14、21天证候疗效优于对照组（P＜0.01）。显效率、总有效率治疗组分别为55.55%（60/108）、89.81%（97/108），对照组分别为37.04%（40/108）、72.22%（78/108），两组比较，差异有统计学意义（P＜0.05）。治疗组喘息、哮鸣音、咳嗽单项症状疗效优于对照组（P＜0.05）。治疗组不良反应发生率［0.92%（1/109）］低于对照组［1.85%（2/108）］（P＜0.01）。 结论龙香平喘胶囊能明显改善支气管哮喘急性发作期患者肺功能，可明显降低“痰瘀阻肺”症状总分，有效改善喘息、哮鸣音、咳嗽单项症状，且用药安全。
Abstract:
ObjectiveTo observe clinical effectiveness and safety of Longxiang asthma-relieving capsules in the treatment of bronchial asthma (BA). MethodsRandomized, double-blinded, double simulated, parallel controlled of positive medicine and multiple centered method was adopted according to the GCP rule of State Food and Drug Administration. All 109 cases of the treatment group took Longxiang asthma-relieving capsules plus simulation agent, and 108 cases of the control group took Juanxiao tablets plus simulation agent, the cases in both groups accepted 14-day double blinded therapy, to perform statistical analysis of clinical effects by the end of therapy. ResultsAfter the treatment, FEV1/FVC and PEF in both groups raised than before the treatment (P<0.01), and therapeutic effects were equivalent in both groups (P>0.05). After the treatment, the difference had no statistical meaning in clinical effects of pulmonary function between both groups (P>0.05). Syndrome integrals at day 14 and 21 after treatment lowered in both groups compared to day seven (P<0.01), and syndrome integrals of the treatment group at day 14 and 21 after treatment were lower than these of the control group over the same period (P<0.01). After the treatment, clinical effects of syndrome in both groups were better than these before the treatment (P<0.01), clinical effects of syndrome of the treatment group at day 14 and 21 after treatment were superior to these of the control group (P<0.01). Marked effective rate and total effective rate of the treatment group were 55.55%(60/108) and 89.81% (97/108) respectively, higher than 37.04% (40/108) and 72.22% (78/108) of the control group, the difference showed statistical meaning between both groups (P>0.05). The treatment group was better than the control group in clinical effects of single symptoms including panting, wheezing rale and cough (P<0.05). The incidence of adverse reaction of the treatment group was [0.92%(1/109)], lower than [1.85%(1/108)] of the control group (P<0.01). ConclusionLongxiang asthma-relieving capsules could obviously improve lung function in BA patients at exacerbation stage, noticeably decrease total scores of the symptoms of "phlegm and stasis obstructing lung", effectively improve single symptoms including panting, wheezing rale and cough, with safe medication.

相似文献/References:

[1]向建华,毛良平,韩鹏凯,等.沙美特罗替卡松联合金水宝胶囊治疗中度非急性发作期支气管哮喘100例临床观察*[J].西部中医药,2013,26(05):97.
　XIANG Jianhua,MAO Liangping,HAN Pengkai,et al.Observation on Salmeterol Fluticasone Combined with JinShuiBao Capsule for 100 Cases of Moderate Bronchial Asthma during the Period of Non Acute Attack[J].Western Journal of Traditional Chinese Medicine,2013,26(10):97.
[2]吴大斌.益气固本汤合俞募配穴敷贴治疗支气管哮喘45例[J].西部中医药,2014,27(10):127.
[3]祝伟,田浩.川芎嗪联合小剂量雷公藤治疗儿童哮喘急性发作期患儿38例[J].西部中医药,2015,28(02):102.
[4]贾红光,罗永伟,陈超,等.对支气管哮喘患者电话随访式健康教育的效果评价[J].西部中医药,2015,28(12):115.
[5]王盛强.中西医结合治疗发作期支气管哮喘48例[J].西部中医药,2014,27(02):110.
　WANG Shengqiang.Treating 48 Cases of Bronchial Asthma at Attack Stage by Integrative Medicine[J].Western Journal of Traditional Chinese Medicine,2014,27(10):110.
[6]玛丽亚,孙学健,严兴海.新疆昌吉地区238例支气管哮喘发作期患者中医证型分布[J].西部中医药,2013,26(12):63.
　MA Liya,SUN Xuejian,YAN Xinghai.TCM Patterns Distribution of 238 Cases of Bronchial Asthma at Exacerbation Stage in Changji of XinJiang[J].Western Journal of Traditional Chinese Medicine,2013,26(10):63.
[7]张晔敏.川芎平喘合剂治疗慢性持续期支气管哮喘74例[J].西部中医药,2014,27(12):64.
[8]张坤,秦慧娟,陈桂花△.基于中医体质的健康管理对支气管哮喘患者远期疗效的影响[J].西部中医药,2019,32(04):123.
　ZHANG Kun,QIN Huijuan,CHEN Guihua.Effects of Health Management on Long-term Outcomes of the Patients with Bronchial Asthma Based on TCM Constitution[J].Western Journal of Traditional Chinese Medicine,2019,32(10):123.
[9]李亚,李春梅,陈茜.加味小青龙汤联合沙美特罗替卡松治疗支气管哮喘疗效观察[J].西部中医药,2020,33(04):103.[doi:10.12174/j.issn.1004-6852.2020.04.31]
　LI Ya,LI Chunmei,CHEN Qian.Clinical Observation on Modified XiaoQinglong Tang Joined with Salmeterol Fluticasone in Treating Bronchial Asthma[J].Western Journal of Traditional Chinese Medicine,2020,33(10):103.[doi:10.12174/j.issn.1004-6852.2020.04.31]
[10]李素娟 彭万胜 陈开泉.基于行为转变理论对支气管哮喘患儿开展延续性护理的效果观察[J].西部中医药,2020,33(S1):94.
　Li Sujuan Peng Wansheng Chen Kaiquan.Observation on the Effects of Carrying out Continuous Care for Children with Bronchial Asthma Based on Trans-theoretical Model[J].Western Journal of Traditional Chinese Medicine,2020,33(10):94.

备注/Memo

备注/Memo:
张玲（1986—），女，博士学位，博士后，讲师。研究方法：研究方向：免疫性疾病的中西医结合防治。国家“十五”重大科技计划项目（2001BA701A-21）；科技部创新基金（03C26226110309）；陕西省发改委高技术产业化示范工程项目（陕发改高技2004367）；中国知识产权专利保护（专利号：CN1485056A）。
更新日期/Last Update: 1900-01-01